Literature DB >> 24821471

Attention-deficit/hyperactivity disorder subtypes and substance use and use disorders in NESARC.

Duneesha De Alwis1, Michael T Lynskey2, Angela M Reiersen1, Arpana Agrawal3.   

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is associated with substance use and substance use disorders (SUD). However, relatively little is known about the relationship between DSM-IV ADHD subtypes and substance use or DSM-IV abuse/dependence in epidemiological samples.
METHODS: Data were obtained from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC, N = 33,588). Respondents reported on ADHD symptoms (DSM-IV) for the period of time when they were 17 years or younger. Lifetime use and DSM-IV abuse/dependence of alcohol, nicotine, cannabis, cocaine, sedatives, stimulants and heroin/opiates were compared across those with ADHD symptoms but no diagnosis (ADHDsx; N = 17,009), the Combined (ADHD-C; N = 361), Predominantly Inattentive (ADHD-I; N = 325), and the Predominantly Hyperactive-Impulsive (ADHD-HI; N = 279) ADHD subtypes. Taking a more dimensional approach, inattentive and hyperactive-impulsive symptom counts and their associations with substance use and misuse were also examined.
RESULTS: After adjustments for conduct disorder, major depressive disorder, any anxiety disorder and other socio-demographic covariates, substance use and SUD were associated with ADHDsx, ADHD-C, ADHD-I and ADHD-HI. Overall, substance use and SUD were more weakly associated with the ADHDsx group compared to the three ADHD diagnostic groups. Statistically significant differences were not evident across the three diagnostic groups. Hyperactive-impulsive symptoms were more consistently associated with substance use and SUD compared to inattentive symptoms.
CONCLUSIONS: ADHD subtypes are consistently associated with substance use and SUD. The relatively stronger association of hyperactive/impulsive symptoms with substance use and abuse/dependence is consistent with the extant literature noting impulsivity as a precursor of substance use and SUD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADHD subtypes; Substance use; Substance use disorders

Mesh:

Year:  2014        PMID: 24821471      PMCID: PMC4135513          DOI: 10.1016/j.addbeh.2014.04.003

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  33 in total

1.  Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A).

Authors:  R C Kessler; S Avenevoli; K A McLaughlin; J Greif Green; M D Lakoma; M Petukhova; D S Pine; N A Sampson; A M Zaslavsky; K Ries Merikangas
Journal:  Psychol Med       Date:  2012-01-25       Impact factor: 7.723

Review 2.  Behavioral disinhibition and the development of early-onset addiction: common and specific influences.

Authors:  William G Iacono; Stephen M Malone; Matt McGue
Journal:  Annu Rev Clin Psychol       Date:  2008       Impact factor: 18.561

3.  The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study.

Authors:  Zheng Chang; Paul Lichtenstein; Henrik Larsson
Journal:  J Abnorm Child Psychol       Date:  2012-04

4.  Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes.

Authors:  Erik G Willcutt; Joel T Nigg; Bruce F Pennington; Mary V Solanto; Luis A Rohde; Rosemary Tannock; Sandra K Loo; Caryn L Carlson; Keith McBurnett; Benjamin B Lahey
Journal:  J Abnorm Psychol       Date:  2012-05-21

5.  Psychometric and genetic architecture of substance use disorder and behavioral disinhibition measures for gene association studies.

Authors:  Brian M Hicks; Benjamin D Schalet; Stephen M Malone; William G Iacono; Matt McGue
Journal:  Behav Genet       Date:  2010-12-12       Impact factor: 2.805

Review 6.  Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.

Authors:  Alice Charach; Emanuela Yeung; Troy Climans; Erin Lillie
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-12-03       Impact factor: 8.829

7.  The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

Authors:  S Bernardi; S V Faraone; S Cortese; B T Kerridge; S Pallanti; S Wang; C Blanco
Journal:  Psychol Med       Date:  2011-08-16       Impact factor: 7.723

Review 8.  Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

Authors:  Steve S Lee; Kathryn L Humphreys; Kate Flory; Rebecca Liu; Kerrie Glass
Journal:  Clin Psychol Rev       Date:  2011-01-20

9.  Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits.

Authors:  M D Glantz; J C Anthony; P A Berglund; L Degenhardt; L Dierker; A Kalaydjian; K R Merikangas; A M Ruscio; J Swendsen; R C Kessler
Journal:  Psychol Med       Date:  2008-12-02       Impact factor: 7.723

10.  Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11.

Authors:  Ujjwal P Ramtekkar; Angela M Reiersen; Alexandre A Todorov; Richard D Todd
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-03       Impact factor: 8.829

View more
  22 in total

1.  Reward Processing in Drug-Naive Youth with Various Levels of Risk for Substance Use Disorders: A Pilot Study.

Authors:  Iliyan Ivanov; Kurt Schulz; Xiaobo Li; Jeffrey Newcorn
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-06-10       Impact factor: 2.576

2.  Primary care reform and funding equity for mental health disorders in Ontario: a retrospective observational population-based study.

Authors:  Imaan Bayoumi; Susan E Schultz; Richard H Glazier
Journal:  CMAJ Open       Date:  2020-06-19

3.  Childhood attention-deficit/hyperactivity disorder symptoms and the development of adolescent alcohol problems: A prospective, population-based study of Swedish twins.

Authors:  Patrick D Quinn; Erik Pettersson; Sebastian Lundström; Henrik Anckarsäter; Niklas Långström; Clara Hellner Gumpert; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-12-30       Impact factor: 3.568

4.  Adult attention-deficit/hyperactivity disorder and its association with substance use and substance use disorders in young men.

Authors:  N Estévez; M Dey; D Eich-Höchli; S Foster; G Gmel; M Mohler-Kuo
Journal:  Epidemiol Psychiatr Sci       Date:  2015-05-20       Impact factor: 6.892

Review 5.  New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 6.  The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings.

Authors:  Deborah S Hasin; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-07-26       Impact factor: 4.328

7.  Changing relationships between smoking and psychiatric disorders across twentieth century birth cohorts: clinical and research implications.

Authors:  A Talati; K M Keyes; D S Hasin
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

8.  Does level of attention deficit-hyperactivity disorder symptoms predicts poor transition into adulthood?

Authors:  Stéphanie Baggio; Joseph Studer; Ana Fructuoso; Véronique S Grazioli; Patrick Heller; Hans Wolff; Gerhard Gmel; Nader Perroud
Journal:  Int J Public Health       Date:  2018-07-25       Impact factor: 3.380

Review 9.  Which came first: Cannabis use or deficits in impulse control?

Authors:  Linda Rinehart; Sade Spencer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-08-11       Impact factor: 5.067

10.  Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients. A 5-Year Follow-Up Study.

Authors:  Alessandro Pallucchini; Marco Carli; Angelo G I Maremmani; Marco Scarselli; Giulio Perugi; Icro Maremmani
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.